Haleon plc (NYSE:HLN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight research firms that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.95.
A number of research firms recently weighed in on HLN. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Sanford C. Bernstein downgraded Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Morgan Stanley lowered shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Finally, HSBC reaffirmed a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th.
Read Our Latest Stock Report on HLN
Haleon Stock Up 1.1 %
Shares of HLN traded up $0.12 during trading hours on Thursday, hitting $10.24. The company had a trading volume of 9,184,324 shares, compared to its average volume of 6,555,334. The company has a market capitalization of $46.33 billion, a PE ratio of 30.10, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The company's fifty day moving average price is $9.94 and its two-hundred day moving average price is $9.87. Haleon has a one year low of $7.99 and a one year high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.
Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, equities analysts forecast that Haleon will post 0.43 earnings per share for the current fiscal year.
Haleon Increases Dividend
The business also recently declared a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. This is an increase from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon's dividend payout ratio (DPR) is presently 58.97%.
Institutional Trading of Haleon
Large investors have recently modified their holdings of the business. Sierra Ocean LLC acquired a new stake in shares of Haleon during the 4th quarter worth $26,000. Versant Capital Management Inc grew its holdings in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Haleon in the fourth quarter valued at about $35,000. Toronto Dominion Bank raised its position in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock valued at $38,000 after acquiring an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management bought a new position in Haleon in the fourth quarter worth about $39,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.
About Haleon
(
Get Free ReportHaleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Stories
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
